[{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"TLR9||Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"TLR9||Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"TLR9||Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kuros Biosciences","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Kuros Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Kuros Biosciences \/ XOMA","highestDevelopmentStatusID":"8","companyTruncated":"Kuros Biosciences \/ XOMA"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Series C Financing","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Longitude Capital","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Longitude Capital"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Checkmate Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"IND Enabling","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Acquisition","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Acquisition","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"University of Iowa Holden Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Checkmate Pharmaceuticals \/ University of Iowa Holden Comprehensive Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Checkmate Pharmaceuticals \/ University of Iowa Holden Comprehensive Cancer Center"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"TLR9","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Diwakar Davar","sponsor":"Checkmate Pharmaceuticals | CellSight Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Diwakar Davar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diwakar Davar \/ Checkmate Pharmaceuticals | CellSight Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Diwakar Davar \/ Checkmate Pharmaceuticals | CellSight Technologies"}]

Find Clinical Drug Pipeline Developments & Deals for Vidutolimod

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Vidutolimod is a Other Large Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          October 03, 2023

                          Lead Product(s) : Vidutolimod

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : The acquisition strengthens Regeneron's portfolio of immuno-oncology candidates, by acquiring Checkmate's pipeline including lead candidate, CMP-001 (vidutolimod), an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 agonist delivered i...

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : $250.0 million

                          May 31, 2022

                          Lead Product(s) : Vidutolimod,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : $250.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : The objective of this study is to determine the dose of CMP-001 (vidutolimod) that, in combination with pembrolizumab, has optimal clinical efficacy and acceptable toxicity in patients with relapsed lymphoma who have failed at least one line of therapy.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          May 26, 2022

                          Lead Product(s) : Vidutolimod,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : University of Iowa Holden Comprehensive Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Regeneron's resources and expertise will help accelerate the development of vidutolimod and realization of the full potential of our virus-like particle (VLP) platform for immunotherapy.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : $250.0 million

                          April 19, 2022

                          Lead Product(s) : Vidutolimod,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : $250.0 million

                          Deal Type : Acquisition

                          blank

                          05

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : CMP-001 (vidutolimod), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          April 08, 2022

                          Lead Product(s) : Vidutolimod,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : CMP-001, an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger body’s innate immune system to attack tumors in combination ...

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          March 08, 2022

                          Lead Product(s) : Vidutolimod,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Vidutolimod triggers the body’s innate immune system to attack tumors in combination with other therapies. XOMA has acquired all future potential royalties from commercial sales of vidutolimod, which are tiered from high-single to double digits.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          July 15, 2021

                          Lead Product(s) : Vidutolimod,Nivolumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : XOMA

                          Deal Size : $32.0 million

                          Deal Type : Acquisition

                          blank

                          08

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Vidutolimod is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Merkel Cell.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          June 07, 2021

                          Lead Product(s) : Vidutolimod

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Checkmate announced development program expansion of vidutolimod (CMP-001) into non-melanoma skin cancers in combination with Libtayo® (cemiplimab) under a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”).

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          May 10, 2021

                          Lead Product(s) : Vidutolimod,Cemiplimab

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Checkmate Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : CMP-001 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Melanoma.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          January 06, 2021

                          Lead Product(s) : Vidutolimod

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank